Table 3. Medications used during the period of the study.
| Concomitant medications – no. (%) | Overall N=778 | Proxalutamide N=423 | Placebo N=355 | p-value |
| Cephalosporins (Cefuroxime, Ceftriaxone, Cefepime) | 659 (84.7%) | 363 (85.8%) | 340 (95.8%) | <0.0001 |
| Colchicine | 576 (74.0%) | 255 (60.3%) | 321 (90.4%) | <0.0001 |
| Macrolides (azithromycin, clarithromycin) | 694 (89.2%) | 356 (84.2%) | 338 (95.2%) | <0.0001 |
| Glucocorticosteroids (dexamethasone, methylprednisolone) | 778 (100.0%) | 423 (100.0%) | 355 (100.0%) | 1.00 |
| Enoxaparin | 767 (98.6%) | 414 (97.9%) | 355 (100.0%) | 0.003 |
| Omeprazole | 778 (100.0%) | 423 (100.0%) | 355 (100.0%) | 1.00 |
| Vancomycin | 51/636 (8.0%) | 3/307 (1.0%) | 48/329 (14.6%) | <0.0001 |
| Meropenem | 97/636 (15.3%) | 16/307 (5.2%) | 81/329 (24.6%) | <0.0001 |
| Piperacillin/Tazobactam | 148/636 (23.3%) | 24/307 (7.8%) | 124/329 (37.7%) | <0.0001 |